anthrax vaccine

Latest Headlines

Latest Headlines

Pfenex enters anthrax vaccines realm with $143.5M BARDA contract

While San Diego-based Pfenex's primary focus isn't on vaccines, the company gained a big backer in the space Monday with the announcement that the U.S. government has agreed to work with the biotech on its anthrax vaccine candidate for bioterror protection.

Emergent BioSolutions nabs government funds to test new-and-improved anthrax vaccine

In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.

Theraclone and PharmAthene merge antibody, vaccine development ops

Theraclone Sciences has struck a deal to merge its antibody development efforts with biodefense drug developer PharmAthene. Once the merger is complete, Theraclone CEO Clifford Stocks will head the expanded company as PharmAthene CEO Eric Richman takes a spot on the board.

Anthrax vax vexes bioethics committee

In 2011 the U.S. government ran a war game to simulate how a San Francisco-sized city would cope with an anthrax attack by terrorists.

FhCMB nabs up to $9.9M from NIH for anthrax vaccine research

Fraunhofer Center for Molecular Biotechnology could receive up to $9.9 million in funding from NIH's National Institute of Allergy and Infectious Diseases to develop the next generation of anthrax vaccines.

U.K.'s HPA lands $6.4M for anthrax vaccine research

The U.S. government doled out a contract worth £4 million ($6.4 million) to the U.K.'s Health Protection Agency to develop a next-generation anthrax vaccine. The project will be valued at £14 million ($22.6 million) if all milestones are met.

HHS shoots down bond plan for risky biotech bets

The Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services (HHS), dismissed a biotech industry proposal for using government bonds rather than contracts to fund projects to advance vaccines and other meds for conditions resulting from bioterrorism, Bloomberg reported.

Cardiff University works on anthrax vaccine for NATO

Scientists from the U.K.'s Cardiff University are leading a NATO project to develop an anthrax vaccine.

Public sector picks up drug and vaccine development again

In a post-9/11 world, fears over pandemics and bioterrorism have renewed drug and vaccine development in the public sector, as national governments funnel research toward combating infectious diseases, like anthrax.

PharmAthene's anthrax vax put on hold as shares plummet

The FDA froze biodefense company PharmAthene's anthrax vaccine, SparVax rPA, sending shares tumbling 17% to $1.21 in recent premarket trading, The Wall Street Journal reports.